Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Purchased by State of Wyoming

State of Wyoming lifted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 44.6% during the fourth quarter, Holdings Channel reports. The fund owned 30,911 shares of the company’s stock after buying an additional 9,530 shares during the quarter. State of Wyoming’s holdings in Cellebrite DI were worth $681,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Gen Wealth Partners Inc acquired a new stake in Cellebrite DI during the fourth quarter valued at $85,000. NewEdge Advisors LLC grew its position in Cellebrite DI by 600.7% during the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock valued at $86,000 after buying an additional 3,352 shares during the period. R Squared Ltd acquired a new stake in Cellebrite DI during the fourth quarter valued at $100,000. Polen Capital Management LLC acquired a new stake in Cellebrite DI during the fourth quarter valued at $222,000. Finally, Victory Capital Management Inc. acquired a new stake in Cellebrite DI during the fourth quarter valued at $234,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Stock Up 0.8%

CLBT opened at $17.41 on Monday. The company has a market cap of $4.17 billion, a price-to-earnings ratio of -12.53, a PEG ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 52-week low of $10.25 and a 52-week high of $26.30. The firm’s fifty day simple moving average is $19.02 and its two-hundred day simple moving average is $20.26.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.01. The business had revenue of $107.55 million for the quarter, compared to the consensus estimate of $109.36 million. Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. The company’s revenue was up 20.0% compared to the same quarter last year. During the same period last year, the firm posted $0.08 earnings per share. On average, research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Needham & Company LLC dropped their price target on shares of Cellebrite DI from $28.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. JPMorgan Chase & Co. dropped their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating on the stock in a research report on Monday, May 12th. Finally, Lake Street Capital raised their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $22.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.